Effects of fluoroquinolone restriction (from 2007 to 2012) on resistance in Enterobacteriaceae: Interrupted time-series analysis

Journal of Hospital Infection

Volumn 91, Issue 1, 2015, Pages 68-73

  Sarma, J B ^a   Marshall, B ^a   Cleeve, V ^a   Tate, D ^a   Oswald, T ^a   Woolfrey, S ^a  

^a NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antimicrobial stewardship; Enterobacteriaceae; Fluoroquinolones; Interrupted time series analysis

Indexed keywords

CARBAPENEM DERIVATIVE; CEFALEXIN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; LEVOFLOXACIN; NITROFURANTOIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TRIMETHOPRIM; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE CTX-M-15; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATION; BLOOD CULTURE; BRONCHIECTASIS; COMMUNITY ACQUIRED PNEUMONIA; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HEALTHCARE ASSOCIATED INFECTION; HUMAN; PATIENT CARE; PHENOTYPE; TIME SERIES ANALYSIS; URINALYSIS; URINARY TRACT INFECTION; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; URINE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CIPROFLOXACIN; CROSS INFECTION; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; FLUOROQUINOLONES; HUMANS; INTERRUPTED TIME SERIES ANALYSIS; MICROBIAL SENSITIVITY TESTS;

EID: 84938291144     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2015.05.006     Document Type: Article

References (16)

1. Rooney P.J., O'Leary M.C., Loughrey A.C., et al. Nursing homes as a reservoir of extended spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009, 64:635-641.
2. Lau S.H., Kaufmann M.E., Livermore D.M., et al. UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone. J Antimicrob Chemother 2008, 62:1241-1244.
3. Rogers B.A., Sidjabat H.E., Paterson D.L. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66:1-14.
4. Cook P.P., Das T.D., Gooch M., Catrou P.G. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents. Infect Control Hosp Epidemiol 2008, 29:716-722.
5. Office for National Statistics. Regional and local statistics. London: ONS. Available at: [last accessed April 2014]. http://www.ons.gov.uk/ons/regional-statistics/index.html.
6. Guidelines for ATC classifications and DDD assignment 2002, World Health Organization Collaborating Center for Drug Statistics Methodology.
7. Gaynes R., Monnet D. The contribution of antibiotic use on the frequency of antibiotic resistance in hospitals. Ciba Found Symp 1997, 207:47-56.
8. Gould I.M. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999, 43:459-465.
9. McGowan J.E. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?. Infect Control Hosp Epidemiol 1994, 15:478-483.
10. Davies J., Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol 2010, 74:417-433.
11. Zhanel G.G., Nicolle L.E., Gin A.S., Karlowsky J., Kabani A., Hoban D.J. Ciprofloxacin or imipenem use correlates with resistance in Pseudomonas aeruginosa. Can J Infect Dis 1998, 9:382-386.
12. Mutnick A.H., Rhomberg P.R., Sader H.S., Jones R.N. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004, 53:290-296.
13. Lipsitch M., Bergstrom C.T., Levin B.R. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci USA 2000, 97:1938-1943.
14. Dhanji H., Doumith M., Rooney P.J., et al. Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum β-lactamases in nursing homes in Belfast, UK. J Antimicrob Chemother 2011, 66:297-303.
15. Dellit T.H., Owens R.C., McGowan J.E., et al. Antimicrobial Stewardship Guidelines. Clin Infect Dis 2007, 44:159-177.
16. Walker E.S., Levy F., Shorman M., David G., Abdalla J., Sarubbi F.A. A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions. J Clin Microbiol 2004, 42:2792-2795.